Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue
- Patrick Chène†1,
- Joëlle Rudloff†1,
- Joseph Schoepfer2,
- Pascal Furet2,
- Peter Meier2,
- Zhiyan Qian1,
- Jean-Marc Schlaeppi3,
- Rita Schmitz3 and
- Thomas Radimerski1Email author
© Chène et al; licensee BioMed Central Ltd. 2009
Received: 25 May 2008
Accepted: 07 January 2009
Published: 07 January 2009
Topoisomerase II poisons are in clinical use as anti-cancer therapy for decades and work by stabilizing the enzyme-induced DNA breaks. In contrast, catalytic inhibitors block the enzyme before DNA scission. Although several catalytic inhibitors of topoisomerase II have been described, preclinical concepts for exploiting their anti-proliferative activity based on molecular characteristics of the tumor cell have only recently started to emerge. Topoisomerase II is an ATPase and uses the energy derived from ATP hydrolysis to orchestrate the movement of the DNA double strands along the enzyme. Thus, interfering with ATPase function with low molecular weight inhibitors that target the nucleotide binding pocket should profoundly affect cells that are committed to undergo mitosis.
Here we describe the discovery and characterization of a novel purine diamine analogue as a potent ATP-competitive catalytic inhibitor of topoisomerase II. Quinoline aminopurine compound 1 (QAP 1) inhibited topoisomerase II ATPase activity and decatenation reaction at sub-micromolar concentrations, targeted both topoisomerase II alpha and beta in cell free assays and, using a quantitative cell-based assay and a chromosome segregation assay, displayed catalytic enzyme inhibition in cells. In agreement with recent hypothesis, we show that BRCA1 mutant breast cancer cells have increased sensitivity to QAP 1.
The results obtained with QAP 1 demonstrate that potent and selective catalytic inhibition of human topoisomerase II function with an ATP-competitive inhibitor is feasible. Our data suggest that further drug discovery efforts on ATP-competitive catalytic inhibitors are warranted and that such drugs could potentially be developed as anti-cancer therapy for tumors that bear the appropriate combination of molecular alterations.
Topoisomerase type II is an ATPase of the GHKL (gyrase, Hsp90, histidine kinase, MutL)-family that is evolutionary conserved in eukaryotes and essential for chromosome segregation during mitosis . Mammals express two topoisomerase type II isoforms, alpha and beta, which are highly homologous but display differences in expression and in sub-cellular localization at the time of mitosis . Like topoisomerases type I and III, the type II enzyme can remove topological constraints on DNA. However, it is the only enzyme that is capable of decatenating intertwined chromatids. Catenations in sister chromatids arise during DNA replication and must be removed to allow faithful chromosome segregation during anaphase . Topoisomerase II is a homodimer that clamps onto two DNA double strands upon ATP binding to the amino-terminal ATPase domains. Subsequently, the enzyme transiently cleaves one of the DNA double strands and, using the energy derived from ATP hydrolysis, transports the second DNA double strand through the gap. The cleaved strand is rapidly religated and the DNA strands are released from the enzyme upon hydrolysis of the second molecule ATP and dissociation of ADP molecules [3, 4]. Drugs that interfere with topoisomerase II function have been developed as antitumor agents and are in clinical use already for decades . However, the vast majority of these drugs act by stabilizing the state in which the enzyme has introduced the DNA double strand break and induce a so-called cleavable complex [6, 7]. Consequently, tumor cell death is triggered by the substantial DNA damage elicited by the so-called topoisomerase II poisons. Despite broad antitumor activity, the use of topoisomerase II poisons as cancer chemotherapy is limited by a narrow therapeutic window as concomitant damage to healthy cells and tissues is almost inevitable .
Drugs that inhibit topoisomerase II function without inducing cleavable complexes are termed catalytic inhibitors . These drugs are thought to impede a step in the catalytic cycle that precedes DNA double strand scission and exert their antiproliferative effects by depleting the essential enzymatic function. Such drugs are thought to mainly affect cells that are committed to undergo mitosis and recent data suggest that tumor cells with defects in certain checkpoint control mechanisms might be particularly sensitive to catalytic inhibitors . It has been proposed that cells employ two distinct checkpoint mechanisms in G2 and M phase, respectively, in response to catalytic topoisomerase II inhibition. In the G2 phase of the cell cycle a "DNA-decatenation checkpoint" is triggered that delays entry of cells into mitosis . This checkpoint was shown to be caffeine sensitive and dependent on ATM/ATR (ataxia-telangiectasia mutated/ATM- and Rad3-related), BRCA1 (breast cancer gene 1) and the WRN (Werner syndrome gene) helicase [12–14]. Interestingly, in one study it was found that a fraction of lung cancer cell lines were hypersensitive toward the bisdioxopiperazine catalytic topoisomerase II inhibitor ICRF-193 . The hypersensitive cells failed to activate ATM and to delay entry into mitosis upon incubation with ICRF-193. Furthermore, recent evidence suggests that cells arrest in metaphase upon depletion of topoisomerase II or treatment with the catalytic inhibitor ICRF-193 [15, 16]. The metaphase arrest was shown to be distinct from the spindle assembly checkpoint but nonetheless to be dependent on the checkpoint protein Mad2 [15, 17]. These data suggest that it may be possible to develop catalytic inhibitors of topoisomerase II as anticancer therapy to target tumors with the appropriate molecular alterations .
The bisdioxopiperazines inhibit the catalytic cycle of topoisomerase II by binding in proximity of the ATP binding site and trapping the enzyme as a closed clamp on DNA . Alternatively, the catalytic cycle can be halted by drugs that dock into the ATP-binding pocket and prevent nucleotide binding. Drugs that target bacterial DNA-gyrase were shown to function by this mechanism of action and have been developed as antibiotics . Notably, recent data suggest that this approach should also be applicable to the eukaryotic enzyme [20–22]. Starting from a homology model derived from DNA-gyrase and subsequently using the yeast  and more recently the human topoisomerase II ATPase domain crystal structures  we have undertaken structure-based drug discovery efforts on this exciting target with the aim of identifying ATP-competitive catalytic inhibitors. Relying on an enzymatic ATPase assay, these efforts have led to the discovery of novel designed purine diamino analogues as potent ATP-competitive catalytic inhibitors of topoisomerase II. The quinoline aminopurine 1 (QAP 1) inhibited topoisomerase II ATPase activity as well as the decatenation reaction and targeted both topoisomerase II alpha and beta isoforms in cell-free assays. Importantly, QAP 1 displayed catalytic enzyme inhibition in cells as shown by antagonism of doxorubicin-induced DNA damage and aberrant chromosome segregation. Finally, we show that breast tumor cells with a mutation in BRCA1 have increased sensitivity towards QAP 1 as compared to cells reconstituted with BRCA1.
Screening for ATP-competitive Topoisomerase II Inhibitors using Molecular Modeling combined with an ATPase Assay
Kinase selectivity profiling of QAP 1 in radiometric filter binding assays
1.7 ± 0.5
1.35 ± 0.05
QAP 1 Inhibits Topoisomerase II Alpha and Beta Isoforms in a Cell Free Assay
QAP 1 displays Catalytic Topoisomerase II Inhibition in a Quantitative Cell-Based Assay
Perturbation of Chromosome Segregation by QAP 1 in a Functional Cellular Assay
BRCA1 Mutant Breast Cancer Cells Display Increased Sensitivity to both Non-ATP-Competitive and ATP-Competitive Catalytic Topoisomerase II Inhibition
The novel rationally designed purine analogue QAP 1 was found to inhibit human topoisomerase II DNA-dependent ATPase activity and DNA decatenation in vitro with submicromolar IC50s and to inhibit the enzyme with an ATP-competitive mode of action. Although purine analogues have recently been described as catalytic inhibitors of topoisomerase II [21, 22], to our best knowledge QAP 1 represents the most potent and selective example of this chemotype described to date. Interestingly, topoisomerase II dimers consisting of one wild-type and one ATPase dead molecule have been found to still be capable of carrying out DNA strand passage reactions in vitro . This suggests that ATP-competitive inhibitors may need to attain intracellular concentrations that saturate both ATP-binding sites of the topoisomerase II dimer for efficient inhibition of DNA decatenation, whereas a single bisdioxopiperazine molecule binds and bridges the ATP-associated dimer molecules .
In vitro QAP 1 displayed greater than 10 fold selectivity over a standard panel of kinases, although some inhibition of the Ret and Src tyrosine kinases was observed. Further optimization will be required to reach low nanomolar potency toward topoisomerase II while improving selectivity over kinases. The recently described crystal structure of the human topoisomerase II ATPase domain is expected to aid such drug discovery efforts ; co-crystallization with purine scaffolds will be crucial to corroborate binding mode and provide further impetus for lead optimization.
Cellular activity of QAP 1 was demonstrated by antagonism of topoisomerase II poison-induced DNA damage and aberrant chromosome segregation, even though ICRF-193 was more potent in both of these assays. On the other hand, in the clonogenic growth assays QAP 1 and ICRF-193 affected BRCA1 mutant cells to a comparable extent at a concentration of 5 μM. Although the bisdioxopiperazine class catalytic inhibitors of topoisomerase II are used for the treatment of adult T-cell leukemia in Japan, their use in other cancer indications has been limited to the modulation of anthracycline-related cardiotoxicity . A key issue in the development of catalytic inhibitors of topoisomerase II is that, although the enzyme is clearly druggable, it is currently not obvious which tumors bearing which kind of molecular alterations will respond particularly well to such drugs and what the effects on normal cells and stem cells will be . It is anticipated that catalytic inhibitors will show less side effects compared to topoisomerase II poisons but will also display a narrower anti-tumor spectrum. Importantly, concepts for exploiting the anti-proliferative activity of catalytic topoisomerase II inhibitors based on molecular characteristics of the tumor cell have recently started to emerge . The discovery of checkpoint mechanisms in G2 and M phase that appear to protect cells transiently from progressing into and through mitosis in the absence of catalytic topoisomerase II function is a promising starting point [12, 15, 16]. The finding that BRCA1 mutant cells displayed slightly increased sensitivity to QAP 1 supports a role of the protein in the response to catalytic topoisomerase II inhibition. Interestingly, BRCA1 appears to have a dual link to topoisomerase II in that it is required (i) to enforce the DNA decatenation checkpoint and (ii) to directly regulate topoisomerase II activity by ubiquitination [12, 42]. Takahashi and colleagues have observed remarkable hypersensitivity of a subset of lung cancer cells to ICRF-193. The hypersensitive cell lines lacked DNA decatenation checkpoint function and appeared to have impaired ATM activation in response to ICRF-193 treatment . However, these cannot be the only criteria since it was found that overriding the DNA decatenation checkpoint with caffeine was not sufficient to render non-sensitive cells hypersensitive to the catalytic inhibitor . Thus, more research will be required to unravel the molecular alterations predictive of a particularly good response to catalytic topoisomerase II inhibitors and the ICRF-193 hypersensitive cell lines alluded to above could be invaluable tools for this purpose. Finally, given the findings of several groups that bisdioxopiperazines can interfere with DNA metabolism and damage DNA [35–37] and that stem and progenitor cells have an inefficient decatenation checkpoint , it will be important to determine the effects of ATP-competitive catalytic topoisomerase II inhibitors in these settings. The potential therapeutic value of potent and selective ATP-competitive inhibitors will also be determined by their impact on non-tumor cells versus sensitive tumor cells in pre-clinical models.
In the present study, we describe a novel purine diamine analogue, termed QAP 1, which emerged from molecular modeling efforts as a potent catalytic inhibitor of topoisomerase II alpha and beta. The inhibitor blocks topoisomerase II ATPase and decatenation activity in biochemical assays and depletes enzyme function in cellular systems. In particular, we show that QAP 1 antagonizes anthracycline-mediated DNA damage as assessed by suppression of γH2AX induction and perturbs chromosome segregation. The inhibitor QAP 1 represents a promising starting point for lead optimization campaigns and further drug discovery efforts. Importantly, the ATP-competitive catalytic inhibitor also represents a novel tool, with distinct mechanism of action as compared to bisdioxopiperazines, to assess the effects of topoisomerase II inhibition in cancer cells and in normal cells. It is the prevailing view that tumor cell sensitivity to catalytic topoisomerase II inhibitors may be attributed to cell lineage and/or specific checkpoint defects. In agreement with previous analyses, the present study shows that BRCA1 mutant cells display increased sensitivity to catalytic topoisomerase II inhibitors. However, many questions remain regarding the checkpoint mechanisms postulated to monitor DNA topology in G2 and M cell cycle phases, respectively. ATP-competitive catalytic topoisomerase II inhibitors such as QAP 1 could be instrumental to screen tumor cell lines and, combined with genetic as well as molecular studies, help identify tumor settings with increased susceptibility.
Chemical synthesis and reagents
Quinoline aminopurine 1 (QAP 1), biotinylated purine analogue 2, purine analogues 3 and 4 (detailed synthesis will be described elsewhere), 17-AAG and ICRF-193 (BIOMOL Research Laboratories Inc., Plymouth Meeting, PA) were dissolved in DMSO to yield 10 mM final concentration and stored at -20°C. Doxorubicin (BIOMOL Research Laboratories Inc., Plymouth Meeting, PA) was dissolved in distilled water to yield 10 mM final concentration and stored at -20°C. All other chemical reagents were analytical grade quality. All cell culture reagents were purchased from AMIMED (Allschwil, Switzerland).
Full length tagged human topoisomerase II alpha protein production
Human topoisomerase II α cDNA was cloned in three successive steps. First the 5' region of the topoisomerase II α gene upstream of the EcoR1 site was amplified by PCR using an ATCC clone (#59748) as template and primers adding a Bgl2 site at its 5' end. The purified PCR product was digested with Bgl2 and EcoR1 and inserted into pFastBac1 (Invitrogen, Carlsbad, USA) previously digested with BamH1 and EcoR1. Then, an EcoR1/Pst1 fragment of the topoisomerase II α ATCC clone was inserted into the EcoR1/Pst1 sites of the plasmid previously obtained. Finally, the 3' end of topoisomerase II α downstream of Pst1 was amplified by a two-step PCR using the ATCC clone as template and primers adding a PreScission-His6-Strep tag and a Sph1 site at the 3' end. This product was subsequently digested with Pst1 and Sph1 and inserted into the corresponding sites of the plasmid previously obtained. The sequence of the inserted gene and flanking regions was verified by DNA sequencing. Topoisomerase II α protein was expressed in Sf21 cells (Invitrogen, Carlsbad, USA) using the Baculovirus system (multiplicity of infection 2.0, 72 h infection). The cell pellet was resuspended in 15 volumes ice cold lysis buffer (50 mM Na2HPO4 pH 7.7, 500 mM NaCl, 10 mM β-mercaptoethanol, 5 mM imidazol, 100 μg/ml PMSF, 2 mM MgCl2 and EDTA-free protease inhibitor cocktail (Roche Diagnostics GmbH)) and homogenized using a Heidolph Diax 600 homogenizer. Following centrifugation for 60 minutes at 48000 g and filtration through a 3 μm Millipore filter the lysate was loaded on a 5 ml HisTrap HP affinity column (GE Healthcare, Sweden), pre-equilibrated in buffer A (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM β-mercaptoethanol and 5 mM imidazol). The column was washed with buffer A containing 20 mM imidazole and the protein was eluted with a gradient of buffer B (250 mM imidazole in buffer A). Pooled fractions containing topoisomerase II protein were loaded on a SPX200 size exclusion column (16/20) equilibrated with 50 mM Tris HCl pH 7.7, 150 mM NaCl and 2 mM DTT, followed by loading on a 10 ml StrepTactin column (IBA, Germany) equilibrated with 100 mM Tris HCl pH 8.0, 150 mM NaCl, 2 mM β-mercaptoethanol, 1 mM EDTA. After a brief washing step, the enzyme was eluted with and stored in 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM β-mercaptoethanol, 1 mM EDTA and 2.5 mM desthiobiotin. Single-use aliquots of enzyme were flash-frozen in liquid nitrogen and stored at -80°C until use.
ATPase assay and kinetic analysis
DNA-dependent ATP hydrolysis of human topoisomerase II α was monitored by measuring the production of inorganic phosphate using acidic molybdate and malachite green . Specific ATPase activity of every batch was tested in a time-course to determine optimal incubation times and enzyme concentrations within the linear range of the assay. Reactions thus contained 10 – 40 nM topoisomerase II (dimer concentration) in reaction buffer (10 mM Tris HCl pH 7.5, 175 mM KCl, 0.1 mM EDTA, 5 mM MgCl2, 2 mM DTT, 2.5% glycerol and 1.7 nM supercoiled pUC18). The specific activity of the human topoisomerase II α enzyme measured in the ATPase assay was 0.24 μmol PO4·min-1·mg-1. Compounds were initially screened at 10 μM concentration and IC50 values were determined if inhibition was greater than 70%. Compounds at the indicated concentrations were added as serial dilutions prepared in DMSO and preincubated for 10 minutes at 37°C on an orbital shaker. Reactions were started by the addition of 400 μM ATP (Sigma, catalog number A2383) and allowed to proceed for 30 minutes. Reactions were terminated by the addition of 200 μl malachite green reagent and the OD was read immediately at 630 nm on a SpectraMax Plus microtiter plate reader using SoftMax Pro software (Molecular Devices). For kinetic analysis, reactions were carried out in duplicate as described above either in the presence of vehicle (DMSO) or QAP 1. Following a preincubation for 5 minutes, ATP was added at the indicated concentrations to start the reactions, which were allowed to proceed for 17 minutes before stopping and reading as above. From these values the OD values obtained at each respective ATP concentration without enzyme were subtracted for background correction. The low signal to noise ratio of the malachite green assay did not permit the study of a broad range of inhibitor concentrations in competition experiments. Low inhibitor concentrations did not result in enough inhibition to clearly demonstrate the effect of the inhibitor and higher inhibitor concentrations gave very weak signals. A compromise was found by carrying out the competition experiments with a single concentration of the inhibitor that gave a good inhibition of enzyme activity while keeping a measurable signal. The equations used to fit these experiments are:
The IC50 of a competitive inhibitive inhibitor should increase in a linear fashion with the concentration of ATP. The measured IC50s were then plotted in function of the ATP concentrations and linear regression analyses were carried out. For calculation of Michaelis-Menten kinetic parameters  data were plotted in XLfit 4 (XLfit 4 curve fitting software for Microsoft Excel, ID Business Solutions Ltd, Guildford, Surrey, United Kingdom) and linearized according to Eadie-Hofstee. In the latter plot data points obtained at the lowest ATP concentration were omitted as these are the most error prone. Mean Km and Vmax values were calculated from two independent experiments.
DNA decatenation assay
Reagents for the assay were purchased from TopoGEN (catalog number 1001–1, TopoGEN, Inc., Port Orange, FL). Topoisomerase II was extracted according to the manufacturer's instructions from nuclei of HL-60 cells (ATCC; American Type Culture Collection, Manassas, Virginia, USA) and contained both isoforms as assessed by Western blotting. Calculation of specific topoisomerase II decatenation activity was based on complete decatenation of a given amount of catenated input DNA (100 ng kDNA) by a defined amount of nuclear extract containing the alpha and beta isoforms or of a defined amount of purified enzyme in a particular amount of time. The topoisomerase II activity from nuclei decatenated 0.07 ng catenated kDNA · min-1 · ng-1 extract. Purified topoisomerase II alpha (see above) decatenated 0.13 ng catenated kDNA · min-1 · ng-1. Vehicle (DMSO) or drug substance at concentrations to yield the desired end concentrations were added and samples were preincubated for 5 minutes at 37°C and 400 rpm in an Eppendorf thermomixer. Reactions were started by adding ATP (to 450 μM final concentration) to each sample and incubation was continued for 20 minutes. Reactions were terminated by placing the samples on ice and adding 4 μl stop/gel loading buffer. 20 μl of each sample were separated by 1% agarose gel electrophoresis. Gels were analyzed under a UV transilluminator and decatenated kDNA products were quantified using AlphaEaseFC (FluorChem 8900) image analysis software version 3.2.3 (Alpha Innotech, San Leandro, CA).
Topoisomerase II α and β were affinity precipitated with biotinylated inhibitor as follows. Exponentially growing HL-60 cells were collected on ice and incubated with hypotonic buffer (10 mM HEPES pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF, 1× protease inhibitor cocktail (Complete Mini, Roche Diagnostics GmbH)) for 15 minutes, then 0.6% v/v NP-40 was added and cells were disrupted using a Dounce homogenizer. Lysates were transferred to 1.5 ml Protein LoBind Eppendorf tubes and nuclei were collected after centrifugation at 8000 rpm for 10 minutes and washed twice with hypotonic buffer. To extract and release chromatin associated topoisomerase II nuclei were incubated for 30 minutes in DNAse buffer (20 mM Tris HCl pH 7.5, 5 mM MgCl2, 1 mM CaCl2, 25 mM NaCl, 0.5 mM EDTA, 1% NP-40, 1 mM DTT, 1 × protease inhibitor cocktail, 0.1 mM PMSF) containing 40 U DNAse I (Roche Diagnostics GmbH) followed by addition of twice concentrated nuclear extraction buffer (20 mM HEPES pH 7.5, 3 mM MgCl2, 20 mM KCl, 50 mM β-glycerophosphate, 840 mM NaCl, 1 mM EDTA, 50 mM PNPP, 1 mM DTT, 1 mM PMSF) and rotation for 1 h in the coldroom. The soluble fraction was obtained following centrifugation at 13000 rpm for 15 minutes. 25 μg nuclear extract were used for the affinity precipitation. The salt concentration was adjusted to 150 mM with nuclear extraction buffer (without NaCl) and the sample volume was toped off to 200 μl with precipitation buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 25 mM β-glycerophosphate, 25 mM NaF, 5 mM EGTA, 1 mM EDTA, 15 mM PPI, 1 mM PMSF). Compounds were preincubated for 30 minutes prior addition of biotinylated purine analogue 2 for 2 h. Streptavidin agarose beads (Novagen, 69203) were washed twice with PBS, blocked for 30 minutes with PBS containing 1% BSA, washed twice with PBS and finally with precipitation buffer. 40 μl equilibrated streptavidin agarose beads were added to the sample and incubation was continued for 1 h. Beads were pelleted by centrifugation at 7000 rpm for 5 minutes and washed thrice with precipitation buffer. During the last wash the beads were transferred to a new tube and the bound fraction was released by boiling for 5 minutes in Laemmli sample buffer. Topoisomerase II α and β were detected by Western blot as described below.
Topoisomerase II α and β siRNA
0.3 × 106 HeLa T-Rex cells (Invitrogen, Paisley, United Kingdom UK) per 6-cm plate were seeded in 2.6 ml of medium without antibiotics. The day after seeding, cells were transfected for 72 hours with stealth RNA oligos (Invitrogen, Paisley, United Kingdom UK): stealth control oligo 1: 5'ACUUCCGAUUCGUGUAACCGAC UUU3'; and stealth control oligo 2: 5'GGGCUA GUUAUAGUCGACACUGGUA3') or with stealth RNA oligos directed against topoisomerase II α and β transcripts (α1: 5'ACUCAGCCUCUUAUGUGCCAAGUUU3'; α2: GGACAACAUUUG AUCCAAGAUCUUA3' and β1: 5'GGGUGAUCUUGAUACUGCAGCAGUA3'). Lipofectamine™ 2000 was used to transfect oligos according to the manufacturer's instructions. Lipofectamine containing medium was replaced 6 hours after transfection by 3 ml of fresh culture medium. Cells were extracted in 200 μl lysis buffer (50 mM Tris-HCl, pH 7.5; 5 mM EDTA; 420 mM NaCl; 0.5% Nonidet P-40 (NP-40); 1 mM Benzamidine; 20 mM NaF and 1.5 mM MgCl2) freshly supplemented with 1 mM PMSF (from 100 mM stock solution in ethanol), 1 mM DTT (from 1 M stock solution) and 1× protease inhibitor cocktail. Lysates were centrifuged at maximum speed in an Eppendorf centrifuge for 10 minutes at 4°C. The nuclear pellet was resuspended in 22 μl of Laemmli sample buffer and boiled at 95°C for 5 minutes. 15 μl of nuclear extracts were subjected to 6% denaturing SDS-PAGE, transferred to PVDF membranes and probed with the anti-topoisomerase II β antibody (sc-13059, Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:1000 in PBS 0.1% Tween) using appropriate secondary antibody and enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech Inc., Buckinghamshire, United Kingdom). After stripping the membrane it was re-probed with a goat anti-topoisomerase II α antibody (sc-5348, Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:2000 in PBS 0.1% Tween). Immunoreactive bands were revealed by HRP-conjugated protein G (Zymed, CA; diluted 1:3000 in PBS 0.1% Tween) using ECL reagents.
Histone extracts of HL-60 or HeLa T-Rex cells for Western blot analysis were prepared as follows: Following treatments, medium was removed and cells were collected/washed with PBS. Cells were centrifuged for 5 minutes at 1500 rpm and 4°C and the cell pellet was resuspended in 300 μl of ice-cold hypotonic buffer (see above). Cells were transferred in a 1.5 ml Eppendorf tube and incubated for 15 minutes on ice. Thereafter, NP-40 was added to the cells to a final concentration of 0.6% (v/v) and cells were disrupted by pumping 10–15 times through a 1 ml syringe connected to a 23-gauge needle. The extract was centrifuged for 10 minutes at 8000 rpm and 4°C. The supernatant (cytoplasmic fraction) was removed and the nuclear pellet was washed once with 500 μl of ice-cold hypotonic buffer for 4 minutes at 8000 rpm. Nuclear proteins were extracted by addition of 22 μl sample buffer and boiling for 3 minutes. Samples were resolved by 15% SDS-PAGE following transfer to PVDF membrane. After blocking, membranes were incubated either with anti-γH2AX (clone JBW301, 05–636, Upstate, Charlottesville, VA, diluted 1:1000 in PBS containing 0.1% Tween 20 and 5% milk) or histone H3 (catalog number 9715, Cell Signaling Technologies Inc., Beverly, MA, diluted 1:1000 in TBS containing 0.1% Tween 20 and 5% milk) antibodies overnight at 4°C. The corresponding horseradish peroxidase conjugated secondary antibodies were diluted 1:3000 and incubated for 1 hour at room temperature and immunoreactive bands were revealed as described above.
In-Cell Western analysis was carried out as follows. HeLa T-Rex cells were seeded at the cell density of 15 × 103 cells per well in black 96-well plates (Greiner Bio-one Vacuette, St Gallen, Switzerland). The day post-seeding, cells were pretreated with increasing concentrations of either ICRF-193, QAP 1 or vehicle (DMSO) for 30 minutes followed by a 2 hours treatment with 1 μM of doxorubicin, or were only treated with the same concentrations of ICRF-193, QAP 1 or vehicle (DMSO) for 2 hours. Treatments were done in triplicate. Cells were directly fixed by adding 100 μl of 3.7% formaldehyde (diluted 1:10 in PBS from a 37% formaldehyde solution; Sigma, Buchs, Switzerland) per well for 10 minutes at room temperature. Cell membranes were permeabilized by 4 washes with 100 μl per well of PBS containing 0.25% Tween-20 for 4 minutes. Cells were blocked with 50 μl per well of Odyssey Blocking Buffer (OBB; LI-COR Biosciences GmbH, Bad Homburg, Germany) for 2 hours at room temperature with gentle agitation. 25 μl per well of γH2AX antibody (clone JBW301, catalogue number 05–636, Upstate, NY) diluted 1:500 in OBB were incubated overnight at room temperature with gentle agitation. Cells were washed 5 times with 50 μl per well of PBS containing 0.1% Tween-20 for 3 minutes and stained with 25 μl per well of goat anti-mouse InfraRedDye 800 antibody (Rocklands Immunochemicals, Inc., Gilbertsville, PA) diluted 1:800 in OBB containing 0.2% Tween-20 for 1 hour at room temperature in the dark. An additional wash with 50 μl per well of PBS containing 0.1% Tween-20 was performed before DNA staining with 50 μl per well of TO-PRO-3 iodide (642/661) (Invitrogen AG, Basel, Switzerland) diluted 1:5000 in OBB for 1 hour at room temperature in the dark. Finally, cells were washed 4 times with 50 μl per well of PBS containing 0.1% Tween-20 for 3 minutes, liquid was removed and plates were kept at 4°C until reading. γH2AX signals were read using the LI-COR Odyssey Infrared Imager with the Odyssey v1.1 software using the 800 nm channel. Blank values correspond to non-specific γH2AX signal detected in wells without primary antibody staining. The means of these values were subtracted from the γH2AX signals to correct for non-specific background. The resulting values for each sample were normalized to the DNA quantity by measuring the corresponding TO-PRO-3 iodide signals. The TO-PRO-3 iodine signals were detected by using the 700 nm channel. The percentage of γH2AX signal was determined for each concentration of ICRF193 and QAP 1 with or without doxorubicin treatment by setting the value for the treatment with vehicle and 1 μM doxorubicin to 100%. To display relative suppression of γH2AX induction and catalytic topoisomerase II inhibition in cells the values measured in the presence of catalytic inhibitor were subtracted from the corresponding value measured at the same concentration of catalytic inhibitor but in the presence of 1 μM doxorubicin. These data were plotted in XLfit 4 (XLfit 4 curve fitting software for Microsoft Excel, ID Business Solutions Ltd, Guildford, Surrey, United Kingdom) to determine the IC50 values of the catalytic topoisomerase II inhibitors by using four parameter logistic calculation.
Chromosome segregation assay
HL-60 cells were treated overnight for 16 hours with 2 μg/ml aphidicolin (Sigma-Aldrich corporation, St. Louis, MO) and released by washing twice PBS and resuspending into fresh medium. After 6 hours release the cells were treated with 1 mM caffeine (Lancaster Synthesis, Heysham, Lancashire, UK) and with catalytic topoisomerase II inhibitor or vehicle for 2 hours. Cells were washed once with PBS and incubated with 56 mM KCl hypotonic solution for 30 minutes. Cells were pelleted and carefully resuspended in Carnoy's fixative. Cells were pelleted as above, supernatant was removed and cells were resuspended again in 2 ml fixative. Chromosome spreads were prepared by dropping 50 μl cell suspension onto microscopy slides. The slides were allowed to dry and then stained for 10 seconds in Hoechst 33342 dye (Molecular Probes, Eugene, Oregon, prepared 1:1000 in PBS from 10 mg/ml stock). After drying, mounting media (Vectashield®, Vector Laboratories, Burlingame, CA) and a cover slip were added. Samples were observed using an immersion oil lens (100 ×, Nikon, Plan Apo VC) by fluorescence microscopy (Nikon Eclipse, E600) in the DAPI channel. Images were acquired using analySIS® software (Soft Imaging System GmbH, Münster, Germany). Representative images were converted to grayscale, inverted and contrast adjusted with Adobe Photoshop. Mitotic cells were categorized as described .
Clonogenic growth assay with HCC1937 cells
HCC1937 BRCA1 mutant and HCC1937 BRCA1 reconstituted breast ductal carcinoma cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 4.5 g/l glucose and 1% (v/v) penicillin/streptomycin. Status of BRCA1 was corroborated by immunoprecipitation using 50 μg nuclear extracts and 1 μg mouse monoclonal antibody MS110 (ab16780, Abcam Inc., Cambridge, MA), which is directed towards the amino-terminus of the protein. Blots were probed with BRCA1 carboxy-terminal specific mouse monoclonal antibody D9 (sc-6954, Santa Cruz Biotechnologies, Santa Cruz, CA) and, following stripping, re-probed with antibody MS110. For assays, 5000 cells in 3 ml medium were seeded per well of 6 well plates in duplicates. The day after, vehicle (DMSO) or compounds were added. After one week medium was exchanged and vehicle or compounds were re-added for an additional two days. To assess proliferation the medium in each well was replaced with 1 ml medium containing 100 μl WST-1 reagent and incubation for 20 minutes at 37°C. Of each sample 110 μl supernatant were transferred into a 96 well plate and the OD was read at 450 nm (filter at 630 nm) on a SpectraMax Plus microtiter plate reader using SoftMax Pro software (Molecular Devices). For background correction, the blank value consisted of 100 μl medium containing 10 μl WST-1. Thereafter, colonies were stained by removing medium, washing cells once with PBS and incubation with 1 ml crystal violet solution for 30 minutes at room temperature. Cells were washed twice with PBS and colonies were counted using an Artec Counter (Model 880, Artec, Dyntatech Laboratories Inc.) with diameter cut-off set to 0.2 mm. Data were expressed as growth or colony numbers relative to vehicle control treatments (100%).
ATM- and Rad3-related
Br east ca ncer gene 1
g yrase, H sp90, histidine k inase, MutL
Half-maximal inhibitory concentration
Phosphate buffered saline
Werner syndrome gene.
The authors wish to thank Thomas Meyer (Novartis Institutes for BioMedical Research, Basel) for kinase selectivity profiling, Roger A. Greenberg for kindly providing BRCA1 mutant and BRCA1 reconstituted HCC1937 cells and Susan Gasser as well as Neil Osheroff for fruitful discussions.
- Wang JC: CELLULAR ROLES OF DNA TOPOISOMERASES: A MOLECULAR PERSPECTIVE. Nature Reviews Molecular Cell Biology. 2002, 3 (6): 430-440. 10.1038/nrm831.View ArticlePubMedGoogle Scholar
- Linka RM, Porter ACG, Volkov A, Mielke C, Boege F, Christensen MO: C-Terminal regions of topoisomerase II alpha and II beta determine isoform-specific functioning of the enzymes in vivo. Nucl Acids Res. 2007, 35 (11): 3810-3822. 10.1093/nar/gkm102.PubMed CentralView ArticlePubMedGoogle Scholar
- Bates AD, Maxwell A: Energy Coupling in Type II Topoisomerases: Why Do They Hydrolyze ATP?. Biochemistry. 2007, 46 (27): 7929-7941. 10.1021/bi700789g.View ArticlePubMedGoogle Scholar
- Schoeffler AJ, Berger JM: Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans. 2005, 33 (Pt 6): 1465-1470.View ArticlePubMedGoogle Scholar
- Hande KR: Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta. 1998, 1400 (1–3): 173-184.View ArticlePubMedGoogle Scholar
- Ross WEGD, Kohn KW: Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta. 1979, 562 (1): 41-50.View ArticlePubMedGoogle Scholar
- Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984, 226 (4673): 466-468. 10.1126/science.6093249.View ArticlePubMedGoogle Scholar
- Degrassi F, Fiore M, Palitti F: Chromosomal Aberrations and Genomic Instability Induced by Topoisomerase- Targeted Antitumour Drugs. Current Medicinal Chemistry – Anti-Cancer Agents. 2004, 4: 317-325. 10.2174/1568011043352920.View ArticlePubMedGoogle Scholar
- Larsen AK, Escargueil AE, Skladanowski A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacology & Therapeutics. 2003, 99 (2): 167-181. 10.1016/S0163-7258(03)00058-5.View ArticleGoogle Scholar
- Damelin M, Bestor TH: The decatenation checkpoint. Br J Cancer. 2007, 96 (2): 201-205. 10.1038/sj.bjc.6603537.PubMed CentralView ArticlePubMedGoogle Scholar
- Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM, Johnson RT: A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature. 1994, 372 (6505): 467-470. 10.1038/372467a0.View ArticlePubMedGoogle Scholar
- Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS, Downes CS, Kaufmann WK: The human decatenation checkpoint. PNAS. 2001, 98 (21): 12044-12049. 10.1073/pnas.221430898.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakagawa T, Hayashita Y, Maeno K, Masuda A, Sugito N, Osada H, Yanagisawa K, Ebi H, Shimokata K, Takahashi T: Identification of Decatenation G2 Checkpoint Impairment Independently of DNA Damage G2 Checkpoint in Human Lung Cancer Cell Lines. Cancer Res. 2004, 64 (14): 4826-4832. 10.1158/0008-5472.CAN-04-0871.View ArticlePubMedGoogle Scholar
- Franchitto A, Oshima J, Pichierri P: The G2-phase Decatenation Checkpoint Is Defective in Werner Syndrome Cells. Cancer Res. 2003, 63 (12): 3289-3295.PubMedGoogle Scholar
- Skoufias DA, Lacroix FB, Andreassen PR, Wilson L, Margolis RL: Inhibition of DNA Decatenation, but Not DNA Damage, Arrests Cells at Metaphase. Molecular Cell. 2004, 15 (6): 977-990. 10.1016/j.molcel.2004.08.018.View ArticlePubMedGoogle Scholar
- Toyoda Y, Yanagida M: Coordinated Requirements of Human Topo II and Cohesin for Metaphase Centromere Alignment under Mad2-dependent Spindle Checkpoint Surveillance. Mol Biol Cell. 2006, 17 (5): 2287-2302. 10.1091/mbc.E05-11-1089.PubMed CentralView ArticlePubMedGoogle Scholar
- Andrews CA, Vas AC, Meier B, Gimenez-Abian JF, Diaz-Martinez LA, Green J, Erickson SL, Waal Vander KE, Hsu W-S, Clarke DJ: A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin. Genes Dev. 2006, 20 (9): 1162-1174. 10.1101/gad.1367206.PubMed CentralView ArticlePubMedGoogle Scholar
- Classen S, Olland S, Berger JM: Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. PNAS. 2003, 100 (19): 10629-10634. 10.1073/pnas.1832879100.PubMed CentralView ArticlePubMedGoogle Scholar
- Oblak M, Kotnik M, Solmajer T: Discovery and Development of ATPase Inhibitors of DNA Gyrase as Antibacterial Agents. Current Medicinal Chemistry. 2007, 14: 2033-2047. 10.2174/092986707781368414.View ArticlePubMedGoogle Scholar
- Lewis RJ, Singh OM, Smith CV, Skarzynski T, Maxwell A, Wonacott AJ, Wigley DB: The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J. 1996, 15 (6): 1412-1420.PubMed CentralPubMedGoogle Scholar
- Jensen LH, Thougaard AV, Grauslund M, Sokilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M: Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors. Cancer Res. 2005, 65 (16): 7470-7477. 10.1158/0008-5472.CAN-05-0707.View ArticlePubMedGoogle Scholar
- Jensen LH, Liang H, Shoemaker R, Grauslund M, Sehested M, Hasinoff BB: A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase II alpha by Substituted Purine Analogs. Mol Pharmacol. 2006, 70 (5): 1503-1513. 10.1124/mol.106.026856.View ArticlePubMedGoogle Scholar
- Wei H, Ruthenburg AJ, Bechis SK, Verdine GL: Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase. J Biol Chem. 2005, 280 (44): 37041-37047. 10.1074/jbc.M506520200.View ArticlePubMedGoogle Scholar
- Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T, Still WC: Macromodel – an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. Journal of Computational Chemistry. 1990, 11 (4): 440-467. 10.1002/jcc.540110405.View ArticleGoogle Scholar
- Cheng Y, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973, 22 (23): 3099-3108. 10.1016/0006-2952(73)90196-2.View ArticlePubMedGoogle Scholar
- Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J: AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Res. 2004, 64 (14): 4931-4941. 10.1158/0008-5472.CAN-03-3681.View ArticlePubMedGoogle Scholar
- Perrin D, van Hille B, Hill BT: Differential sensitivities of recombinant human topoisomerase II alpha and beta to various classes of topoisomerase II-interacting agents. Biochemical Pharmacology. 1998, 56 (4): 503-507. 10.1016/S0006-2952(98)00082-3.View ArticlePubMedGoogle Scholar
- Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M, Aratani Y, Koyama H, Sekimizu K: Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase II alpha. Genes to Cells. 2003, 8 (4): 393-402. 10.1046/j.1365-2443.2003.00643.x.View ArticlePubMedGoogle Scholar
- Yang X, Li W, Prescott ED, Burden SJ, Wang JC: DNA Topoisomerase II and Neural Development. Science. 2000, 287 (5450): 131-134. 10.1126/science.287.5450.131.View ArticlePubMedGoogle Scholar
- Sakaguchi A, Kikuchi A: Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J Cell Sci. 2004, 117 (7): 1047-1054. 10.1242/jcs.00977.View ArticlePubMedGoogle Scholar
- Carpenter AJ, Porter ACG: Construction, Characterization, and Complementation of a Conditional-Lethal DNA Topoisomerase II alpha Mutant Human Cell Line. Mol Biol Cell. 2004, 15 (12): 5700-5711. 10.1091/mbc.E04-08-0732.PubMed CentralView ArticlePubMedGoogle Scholar
- Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB: Chinese Hamster Ovary Cells Resistant to the Topoisomerase II Catalytic Inhibitor ICRF-159: A Tyr49Phe Mutation Confers High-Level Resistance to Bisdioxopiperazines. Cancer Res. 1998, 58 (7): 1460-1468.PubMedGoogle Scholar
- van Attikum H, Gasser SM: THE HISTONE CODE AT DNA BREAKS: A GUIDE TO REPAIR?. Nature Reviews Molecular Cell Biology. 2005, 6 (10): 757-765. 10.1038/nrm1737.View ArticlePubMedGoogle Scholar
- Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, Luan P, Vlahos CJ, Schutz-Geschwender A, Olive DM: A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Analytical Biochemistry. 2005, 338 (1): 136-142. 10.1016/j.ab.2004.11.015.View ArticlePubMedGoogle Scholar
- Huang K-C, Gao H, Yamasaki EF, Grabowski DR, Liu S, Shen LL, Chan KK, Ganapathi R, Snapka RM: Topoisomerase II Poisoning by ICRF-193. J Biol Chem. 2001, 276 (48): 44488-44494. 10.1074/jbc.M104383200.View ArticlePubMedGoogle Scholar
- Hajji N, Pastor N, Mateos S, Domínguez I, Cortés F: DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat Res. 2003, 530: 1-2.View ArticleGoogle Scholar
- Park I, Avraham HK: Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1. Experimental Cell Research. 2006, 312 (11): 1996-2008. 10.1016/j.yexcr.2006.02.029.View ArticlePubMedGoogle Scholar
- Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M: DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell. 1987, 50 (6): 917-925. 10.1016/0092-8674(87)90518-6.View ArticlePubMedGoogle Scholar
- Holm C, Stearns T, Botstein D: DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol. 1989, 9 (1): 159-168.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikhailov A, Shinohara M, Rieder CL: Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol. 2004, 166 (4): 517-526. 10.1083/jcb.200405167.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang LH-C, Schwarzbraun T, Speicher MR, Nigg EA: Persistence of DNA threads in human anaphase cells suggests late completion of sister chromatid decatenation. Chromosoma. 2007Google Scholar
- Lou Z, Minter-Dykhouse K, Chen J: BRCA1 participates in DNA decatenation. Nat Struct Mol Biol. 2005, 12 (7): 589-593. 10.1038/nsmb953.View ArticlePubMedGoogle Scholar
- Skouboe C, Bjergbaek L, Oestergaard VH, Larsen MK, Knudsen BR, Andersen AH: A Human Topoisomerase IIalpha Heterodimer with Only One ATP Binding Site Can Go through Successive Catalytic Cycles. J Biol Chem. 2003, 278 (8): 5768-5774. 10.1074/jbc.M210332200.View ArticlePubMedGoogle Scholar
- Damelin M, Sun YE, Sodja VB, Bestor TH: Decatenation checkpoint deficiency in stem and progenitor cells. Cancer Cell. 2005, 8 (6): 479-484. 10.1016/j.ccr.2005.11.004.View ArticlePubMedGoogle Scholar
- Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA: An improved assay for nanomole amounts of inorganic phosphate. Analytical Biochemistry. 1979, 100 (1): 95-97. 10.1016/0003-2697(79)90115-5.View ArticlePubMedGoogle Scholar
- West KL, Turnbull RM, Willmore E, Lakey JH, Austin CA: Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase II beta: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability. Nucl Acids Res. 2002, 30 (24): 5416-5424. 10.1093/nar/gkf677.PubMed CentralView ArticlePubMedGoogle Scholar
- McGuinness BE, Hirota T, Kudo NR, Peters J-M, Nasmyth K: Shugoshin Prevents Dissociation of Cohesin from Centromeres During Mitosis in Vertebrate Cells. PLoS Biology. 2005, 3 (3): e86-10.1371/journal.pbio.0030086.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.